文献速递血栓与止血

下一代因子VIII模拟双特异性抗体(Mim8)对因子VIII活性及凝血酶生成检测的影响

The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
PubMed 文献 · J Thromb Haemost · 2023-01-02

本研究将Mim8加入先天性重度血友病A血浆中,评估APTT、因子VIII活性(FVIII:C)及凝血酶生成检测的敏感性。结果显示基于APTT的检测对Mim8敏感,含人蛋白的显色检测敏感性不一,仅牛源显色检测基本不敏感;凝血酶生成在Mim8浓度增加时恢复正常。

要点

  • 基于APTT的检测对Mim8敏感,不应在药物存在下进行。
  • 仅牛源显色检测对Mim8基本不敏感,含人蛋白显色检测敏感性不一。
  • 凝血酶生成在Mim8浓度增加时恢复正常。

核心结论

  • 基于APTT的检测对Mim8敏感,不应在药物存在下进行。
  • 含人蛋白或人/牛杂合蛋白的显色检测对Mim8敏感性不一,仅牛源显色检测基本不敏感。
  • 凝血酶生成在Mim8浓度增加时恢复正常。
  • 改良一步法和显色法可用于定量血浆中Mim8浓度。

研究设计与样本

  • 在先天性重度血友病A血浆中加入Mim8,浓度范围为0 μg/mL至20 μg/mL。
  • APTT用4种试剂测定,一步法FVIII用9种试剂测定,显色法FVIII用6种检测方法测定。
  • 凝血酶生成在低组织因子系统中评估。

主要发现

  • 在1-μg/mL Mim8时,APTT缩短至正常范围内,且所有APTT试剂的一步法FVIII:C均>1.00 IU/mL。
  • 用Mim8参考物质校准的改良一步法,在大多数APTT试剂中回收率在目标Mim8浓度的20%以内。
  • 仅牛源显色检测的FVIII:C在所有Mim8浓度下均<0.04 IU/mL。
  • 仅人源显色检测的FVIII:C在20-μg/mL Mim8时>4.00 IU/mL。
  • 杂合牛FX、人FIXa显色检测的FVIII:C在20-μg/mL Mim8时为0.076至>3.00 IU/mL。

关键数值与推荐

  • 在1-μg/mL Mim8时,所有APTT试剂的一步法FVIII:C均>1.00 IU/mL。
  • 仅牛源显色检测的FVIII:C在所有Mim8浓度下均<0.04 IU/mL。
  • 仅人源显色检测的FVIII:C在20-μg/mL Mim8时>4.00 IU/mL。
  • 杂合牛FX、人FIXa显色检测的FVIII:C在20-μg/mL Mim8时为0.076至>3.00 IU/mL。
  • 正常凝血酶生成在5-μg/mL Mim8时恢复。

临床怎么用

  • 基于APTT的检测对Mim8敏感,不应在药物存在下进行。
  • 改良一步法和显色法可用于定量血浆中Mim8浓度。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mim8 is a next generation bispecific antibody developed for the prophylactic treatment of hemophilia A. The sensitivity of activated plasma thromboplastin time (APTT), assays measuring factor VIII activity (FVIII:C) and thrombin generation to plasma containing Mim8 was assessed. METHODS: Congenital severe hemophilia A plasma was spiked with Mim8 at 0 μg/mL to 20 μg/mL. APTT was measured with 4 reagents, one-stage FVIII with 9 reagents, and chromogenic FVIII with 6 assays. Thrombin generation was assessed in a low tissue factor system. RESULTS: At 1-μg/mL Mim8, the APTT was shortened to within normal limits and one-stage FVIII:C was >1.00 IU/mL with all APTT reagents. Modified one-stage assays calibrated with Mim8 reference material calibrated recovered within 20% of the target Mim8 concentration with most APTT reagents. Factor VIII:C of bovine only chromogenic assays was <0.04 IU/mL at all Mim8 concentrations. Factor VIII:C of human only chromogenic assay was >4.00 IU/mL at 20-μg/mL Mim8. Factor VIII:C of hybrid bovine FX, human FIXa chromogenic assays ranged from 0.076 to >3.00 IU/mL at 20-μg/mL Mim8. Normal thrombin generation was restored at 5-μg/mL Mim8. CONCLUSIONS: APTT-based assays are sensitive to Mim8 and should not be performed in the presence of the drug. Chromogenic assays containing human proteins or hybrid human/bovine proteins demonstrated variable sensitivity to Mim8. Bovine only chromogenic assays were largely insensitive to the presence of Mim8. Thrombin generation normalized at increased Mim8 concentrations. Modified one-stage and chromogenic assays could be used to quantify the Mim8 concentration in plasma.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Bowyer AE, Kitchen S, Ezban M, et al. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation. J Thromb Haemost. 2023. PMID: 36696203. doi:10.1016/j.jtha.2022.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。